Calcinin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Calcinin

Property Description
Active Ingredient Calcitonin Salmon
Form Injectable Solution, Nasal Spray
Pharmacological Class Parathyroid and Anti-Osteoporosis Agent, Bone Metabolism Regulator
General Purpose Slows bone breakdown and regulates calcium balance
Origin Synthetic polypeptide hormone (Salmon-derived)

Calcinin is a prescription-only biopharmaceutical medicine whose active component, Calcitonin Salmon (INN), is utilized to help manage the body's calcium and bone regulatory processes. It is explicitly classified as a Parathyroid and Anti-Osteoporosis Agent and a Hypocalcemic Agent. This classification reflects its role in mineral homeostasis, a process clinically recognized for influencing the body's calcium levels.

What Type of Medicine is Calcinin (Calcitonin Salmon)?

Calcinin is a peptide drug that contains a synthetic version of the Calcitonin Salmon polypeptide hormone. The active ingredient is a synthetically produced 32-amino acid peptide. This salmon-derived molecule is preferred in pharmaceutical preparations because it exhibits greater potency and a longer biological duration of action in humans compared to the natural human calcitonin analogue. This profile ensures a more sustained therapeutic effect.

Calcinin’s General Purpose and Mechanism Summary

The general therapeutic purpose of Calcinin is to help conserve existing bone mass and contribute to the regulation of systemic calcium levels. The active substance achieves this by acting as an agonist on the calcitonin receptor, which directly inhibits the function of specialized cells known as osteoclasts. This means the medication fundamentally works to reduce the rate of bone resorption (the breakdown of old bone). By effectively slowing this process, the drug aids in maintaining the overall structural stability of the skeleton and contributes to a lowering of serum calcium concentration.

Why Is Calcinin Available Only as a Spray or Injection?

Calcinin is available exclusively as an Injectable Solution or as a Nasal Spray. This necessity is dictated by the drug's fundamental nature as a polypeptide molecule. If Calcitonin Salmon were taken orally, the digestive enzymes in the gastrointestinal tract would rapidly degrade its complex protein structure, rendering it entirely inactive. Therefore, these non-oral routes are essential for absorption, making Calcinin specifically positioned as a solution for effective systemic peptide delivery.

Regulatory References

  1. Calcitonin - StatPearls - NCBI Bookshelf

What side effects are possible with Calcinin?

Possible Side Effects and Safety Information

The officially documented safety profile for Calcinin (Calcitonin Salmon) is classified based on clinical trial data and post-marketing experience, utilizing the standard regulatory framework for organizing adverse reactions by frequency and physiological system. This structure is governed by health authorities such as the FDA and EMA.

Frequency-Classified Adverse Reactions

Adverse reactions are grouped based on their observed incidence:

  • Very Common: Includes transient flushing of the face or upper body, and nausea (with or without vomiting). Nausea is often more evident upon the initiation of therapy and may diminish over time.
  • Common: Reactions like headache, dizziness, back pain, and arthralgia (joint pain) are commonly reported. Administration-specific effects include local injection site inflammation for the injectable form and rhinitis (nasal irritation/dryness) for the nasal spray.

Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight several severe and clinically significant reactions. These include serious hypersensitivity reactions, such as anaphylactic shock and swelling of the throat, and cases of severe hypocalcemia which may present with symptoms like tetany and seizures.

Long-term exposure has been associated with an officially documented increased risk of overall malignancy in a meta-analysis, a factor considered in regulatory safety assessments. For users of the nasal spray, periodic nasal examinations are recommended, and the product should be discontinued if severe nasal mucosal ulceration occurs. Furthermore, pre-existing hypocalcemia must be corrected before Calcinin treatment is started.

Population-Specific Safety Notes

The safety and efficacy of Calcitonin Salmon have not been established in the pediatric population. Regulatory guidance notes that use is not indicated in pregnancy and not recommended during lactation.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information for Calcinin (Calcitonin Salmon) overdose focuses on the potential for exaggerated pharmacological effects and the critical need to address severe reactions. This information is based strictly on governmental documents, such as the FDA Prescribing Information and the EMA Summary of Product Characteristics (SmPC).


Documented Overdose Manifestations

Overdose presentations are generally characterized by an exaggeration of known effects and are documented as dose-dependent. Manifestations may include nausea, vomiting, flushing (of the face or hands), and dizziness. A severe outcome from exaggerated pharmacological action is Hypocalcemia (low serum calcium), which may be associated with signs like tetany (muscle cramps) or seizure activity.

Required Emergency Actions

The regulatory labels stipulate that no specific antidote is known for Calcitonin Salmon overdose. If overdose occurs, management is restricted to symptomatic and supportive treatment. Furthermore, immediate medical attention must be sought for signs of severe hypersensitivity reactions, including bronchospasm, swelling of the throat, or anaphylactic shock, as these are documented risks that require urgent clinical intervention. Monitoring of serum calcium is required in patients at risk for hypocalcemia.

Therapeutic Uses of Calcinin

What Calcinin Treats: Main Uses and Benefits


Calcinin is commonly used to address conditions involving systemic imbalance and increased physiological strain. It is relevant in contexts marked by increased discomfort or tension, applied across specific domains where short-term symptomatic support is needed. This is relevant for managing symptoms associated with conditions linked to systemic imbalance, such as specific bone and calcium-related manifestations.

Supporting Comfort During Symptomatic Discomfort

Calcinin is applied in clinical settings for certain distressing symptoms. It provides support that helps ease the overall symptom burden, supports the patient during difficult episodes by easing the overall symptom load, and supports general well-being during symptomatic phases.

Managing Episodic and Disruptive Symptoms

The medicine is considered relevant in conditions characterized by periods of heightened symptoms—specifically those involving localized discomfort or functional stress—that create noticeable interference with daily stability. It helps address symptom clusters that may become intense or fluctuate, contributing to improved day-to-day comfort during these symptomatic periods and may provide supportive relief when symptoms interfere with routine activities.

Quick Fact: Relevant for Heightened Physiological Strain Calcinin is commonly used when symptoms linked to organ-specific functional stress require temporary symptomatic assistance.

Eligibility and Restrictions for Use

The eligibility for using Calcinin (Calcitonin Salmon) is strictly defined by regulatory documentation concerning specific medical conditions, age, and reproductive status.

Eligibility Scope

Classification Eligible Populations (as stated in label)
Allowed Adults with symptomatic Paget’s disease of bone or hypercalcemia (high calcium levels).
Allowed (Conditional) Postmenopausal women (greater than five years postmenopause) for osteoporosis, specifically when alternative treatments are unsuitable.
Contraindicated Patients with a known hypersensitivity to calcitonin-salmon or any of the excipients.

Regulatory Restrictions

  • Age-Related Rules: Safety and efficacy have not been established in the pediatric population (children and adolescents).
  • Reproductive Status: Calcinin Nasal Spray is not indicated for use in females of reproductive potential, including pregnant or breastfeeding women.
  • Pre-existing Conditions: Use requires the prior correction of hypocalcemia (low calcium levels) and the effective treatment of conditions like Vitamin D deficiency.
  • Long-Term Use: For patients on long-term therapy, the need for continued treatment should be re-evaluated periodically due to regulatory concerns regarding a possible association with malignancy.

Connection to the Overall Eligibility Profile

The regulatory structure for Calcinin defines who can and cannot use the medicine by establishing an absolute contraindication based on allergic risk and by excluding populations (pediatric, reproductive) where use is not indicated or not established. Furthermore, official labeling requires that a patient's mineral status must be corrected before treatment begins, defining a clear set of conditional eligibility rules.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section details only the official interaction information documented in government regulatory sources, such as the FDA and EMA.


Interaction Scope

Property Description
Medicinal product categories with documented interactions: Agents affecting mineral homeostasis (Bisphosphonates), drugs subject to renal clearance (Lithium), and essential supplements.
Specific interacting medicines (if explicitly listed): Lithium, Bisphosphonates (as a class).
Mechanistic basis of interactions (only if stated in label): Pharmacodynamic (PD) via additive effect; Pharmacokinetic (PK) via increased urinary clearance of lithium.
Population-specific interaction notes (if applicable): Lower metabolic clearance is observed in patients with End-Stage Renal Failure (ESRF); however, the clinical relevance of this finding is not known by regulators.
Interaction-related restrictions: No specific drug-drug combinations are listed as formally contraindicated.

Interaction Classifications

Classification Description
Interaction severity classification: Not formally assigned; interactions are described as potential effects (e.g., additive calcium-lowering).
Regulatory basis: U.S. FDA Prescribing Information and EMA Summary of Product Characteristics (SmPC).
Interaction-context constraints: The official labeling explicitly states that formal studies designed to evaluate drug interactions have not been conducted, which limits the documented interaction profile.

Resulting Interaction Structure

Official interaction statements:

  • Co-administration with bisphosphonates may result in an additive calcium-lowering effect.
  • Concomitant use with lithium may lead to a reduction in plasma lithium concentrations, attributed to increased urinary clearance.
  • Treatment is officially recommended to be used in conjunction with adequate intake of calcium and vitamin D.
  • Formal drug interaction studies have not been performed, meaning official data for enzyme- or transporter-mediated interaction pathways is not documented.

Connection to the overall interaction profile: The official interaction profile is defined by a limited, specific set of documented interactions related to mineral homeostasis and renal clearance. This profile is primarily constrained by the regulatory statement that formal drug interaction studies have not been conducted for the product. Consequently, official data regarding enzyme- or transporter-mediated interaction pathways are not documented in the prescribing information.

Mechanism of Action

The active component, Calcitonin Salmon, functions through two primary and distinct mechanistic domains: the modulation of bone metabolism and the modulation of nociceptive signaling pathways.

Targeted Action to Inhibit Bone Resorption

The drug acts as a direct agonist that selectively engages the Calcitonin Receptor (CTR), a specialized receptor highly expressed on bone-degrading cells known as osteoclasts. This receptor binding immediately triggers a powerful intracellular cascade that rapidly shuts down the osteoclast's activity, leading to the inhibition of bone resorption and a reduction in the rate of bone mineral degradation.

Dual Mechanism for Systemic Calcium Regulation

In addition to its effect on bone, Calcinin mechanistically modulates the processes governing mineral homeostasis via a second pathway in the kidneys. By interacting with CTRs on renal tubular cells, the drug decreases the reabsorption of calcium and phosphate, leading to their increased urinary excretion. This combined action of reduced bone mineral release and increased renal clearance results in a rapid and measurable hypocalcemic effect on the bloodstream's calcium concentration.

Separate Mechanism for Nociceptive Modulation

Calcinin also exerts an independent anti-nociceptive action by influencing neural pathways in the Central Nervous System. This mechanism, which is distinct from its effects on bone and calcium, is associated with the modulation of specific serotonin receptors and the adjustment of sodium channel function in afferent (nociceptive) nerves, consequently influencing nociceptive impulse transmission.

Dosage and Administration Information

Instruction Map: How to Use Calcinin — Administration Guidelines

Calcinin (Calcitonin Salmon) administration is governed by specific guidelines detailing the precise methods and schedules of use. The medication is delivered via non-oral routes due to its composition as a peptide hormone.


Administration Scope

Entity Instruction
Route of administration Intranasal (via spray), Subcutaneous (SC) injection, or Intramuscular (IM) injection.
Dosing schedule Nasal Spray: 200 IU once daily. Injection: Initial dose often 100 IU daily, reducible for maintenance, or 4-8 IU/kg body weight for acute management.
Timing in relation to meals No explicit requirements regarding use with or without food are cited.
Preparation requirements Nasal Spray: Requires priming prior to initial use. Injection: Solution must be visually inspected to be clear and colorless.
Age-group administration rules No universal dosage adjustment is required for older adults. Use in pediatric patients is generally not supported due to insufficient evidence.
Missed-dose rules If a dose is missed, the patient should not take a double dose; the next scheduled dose should be taken at the proper time.
Special procedural conditions Nasal Spray: Must be administered via alternating nostrils each day. Injection: Injection sites must be rotated.

Instruction Classifications (High-Level)

Classification Pattern/Type
Administration method type Parenteral (Injection) and Mucosal (Intranasal).
Frequency pattern Once daily, Every other day, or Multiple times per day (e.g., 4-8 hourly).
Regulatory basis Established government and regulatory standards.
Use-context constraints Must be administered concurrently with adequate calcium and Vitamin D supplementation.

Resulting Procedural Structure

Official step sequence:

  • Determine the appropriate administration route and form based on the specific condition.
  • Prepare the product immediately prior to use by priming or visual inspection.
  • Administer the labeled numerical dose according to the prescribed frequency (daily, intermittent, or multiple times per day).
  • Maintain the administration procedure by rotating injection sites or alternating nostrils with each dose.

Connection to the overall use protocol: The instructions establish a precise protocol that dictates specific non-oral delivery methods, fixed numerical dose ranges, and the required frequencies of administration. This structured framework includes mandatory procedural steps, such as rotating sites or priming the device, to ensure the drug is used exactly as intended. The protocol integrates the drug's use with concurrent non-drug measures, specifically calcium and Vitamin D, to complete the usage mandate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Calcinin

Calcinin has been studied for its role in regulating bone activity and calcium balance across several different clinical situations. The available evidence comes primarily from Randomized Controlled Trials (RCTs), which compare the medicine against a control, and meta-analyses, which combine the findings of multiple studies to look for patterns observed in the studies.


Evidence for Use in Postmenopausal Osteoporosis

Research has explored Calcinin (Calcitonin Salmon) in research settings for postmenopausal osteoporosis, a condition marked by bone thinning. Large-scale RCTs were used in research exploring how symptoms change over time and was evaluated in women many years past menopause. The main focus of these studies was to monitor changes in Bone Mineral Density (BMD) and to evaluate the occurrence of new vertebral fracture events over the course of several years.

Studies examined data on vertebral fracture occurrence compared to control groups. However, research is ongoing and has consistently highlighted that the effect on other types of breaks, known as non-vertebral fractures (like hip fractures), is not fully established in the evidence.

Furthermore, when researchers combined data from multiple long-term trials, a signal was observed in some studies indicating a potential association with an increased incidence of malignancy compared to control groups. Due to this finding, regulators have reviewed and issued specific conclusions regarding the evidence base for its use.


Evidence for Short-Term Symptom Management

Calcinin was also studied for its role following certain bone breaks. Short-term randomized trials were conducted during periods of increased symptom activity and studies explored outcomes related to physical discomfort and pain in patients with recent osteoporotic fractures. Research highlights changes measured during the study period where reported pain scale measurements were monitored compared to those receiving supportive care alone. However, the study of Calcinin for this purpose is limited to short-term symptomatic support.


Key Areas of Research Uncertainty and Gaps

Key areas of research uncertainty include the lack of consistent evidence regarding non-vertebral fractures. The association with a potential increased incidence of malignancy observed in some studies using the medicine over extended periods, combined with the lack of robust, long-term efficacy data, contributes to a research gap concerning the overall risk-benefit profile for long-term use.

Frequently Asked Questions (FAQ)

Common questions about Calcinin (FAQ)


Q: How long does it typically take to start noticing an effect from Calcinin?

The time it takes to see an effect can vary depending on the condition being addressed. For managing high calcium levels (hypercalcemia), a reduction in serum calcium concentration has been observed within approximately two hours after the first injection. For chronic conditions like Paget’s disease, clinical effects may take several months to become apparent.


Q: Why do some people say Calcinin makes them feel tired?

Tiredness, or fatigue, is not consistently listed as a common side effect in official product information. However, regulatory documents do report other related effects that influence the Central Nervous System (CNS) as common adverse reactions, including dizziness and headache. The official documentation for Calcinin only lists effects that were formally reported during trials or post-marketing surveillance.


Q: Does Calcinin have any known interactions with herbal supplements?

According to official documentation, formal drug interaction studies—including those with various herbal supplements—have not been conducted. Therefore, regulatory agencies have not documented specific data on these potential interactions in the official labeling.


Q: Do I need to avoid certain foods while taking Calcinin?

Regulatory documents state that there are no specific requirements or warnings to avoid particular foods while using Calcinin. However, treatment for bone-related conditions is generally noted to be used in conjunction with adequate intake of calcium and Vitamin D.


Q: How quickly is Calcinin eliminated from the body?

Official pharmacological information indicates that Calcinin is eliminated from the body quite rapidly. The elimination half-life, which describes how quickly the drug leaves the bloodstream, is approximately 58–64 minutes for the injectable form and around 18–23 minutes for the nasal spray.


Q: Can Calcinin affect the results of blood tests?

Yes, regulatory documents mention that Calcinin can influence certain laboratory measurements. It may affect serum calcium levels due to its role in calcium regulation. Some reports also mention monitoring for urine sediment abnormalities (changes in urine composition) in the official prescribing information.


Q: Does Calcinin lose its effectiveness over time?

Official labeling notes that some patients may develop circulating antibodies to the active ingredient, calcitonin salmon. If an initial response is noted but the patient later stops responding, the possibility of antibody formation is suggested for consideration by a prescriber.


Q: Are there any specific populations where Calcinin is described as less effective?

Official documents state that for individuals with Paget’s disease who have received prior treatment with certain other bone medications, such as diphosphonates, the anti-resorptive response to Calcinin may be reduced.


Q: Is Calcinin metabolized by the liver?

The active ingredient in Calcinin is primarily metabolized (broken down) into inactive fragments in the kidneys. Additional breakdown occurs in the blood and surrounding peripheral tissues, but the liver is not cited as the primary site of metabolism.


Q: Does Calcinin affect sleep patterns?

Official documentation for the injectable form lists nocturia (an increase in the need to urinate at night) as a reported side effect. This symptom is noted as potentially influencing sleep patterns.


Q: Why do patients sometimes have to adjust their dose after starting Calcinin?

For the injectable form, official dosing guidelines note that the initial dose is often reduced to a lower maintenance dose once an adequate response to the therapy is achieved. This is a regulated process to manage long-term treatment effectively.


Q: Can Calcinin cause long-term kidney issues?

Regulatory documents mention reports of urine sediment abnormalities (coarse granular casts) being noted in studies. However, these changes were observed to have normalized after the drug was stopped, and no other evidence of renal abnormality has been noted in the available regulatory data.


Q: Are the side effects of Calcinin permanent?

According to official product information, many common side effects are considered transient. For instance, reactions like nausea are typically most noticeable when treatment begins and tend to decrease or disappear with continued administration, suggesting these effects are temporary.


Q: Does Calcinin interact with common painkillers like ibuprofen?

Official regulatory documents state that formal drug interaction studies with specific over-the-counter painkillers, such as ibuprofen, have not been conducted. Therefore, official data on these potential interactions are not documented.


Q: Can I take Calcinin with my daily multivitamins?

Official labeling suggests using Calcinin in conjunction with adequate intake of calcium and Vitamin D. While there is no specific data on all components of a multivitamin, the requirement for mineral support is explicitly documented.


Q: What is the general duration of Calcinin treatment?

Calcinin is utilized for both short-term use (for managing symptoms) and in studies involving long-term therapy (for osteoporosis). Official guidance states that long-term use requires periodic re-evaluation by a prescriber due to regulatory concerns.


Q: How common are serious side effects like allergic reactions to Calcinin?

Serious reactions like anaphylactic shock (a severe allergic reaction) have been reported. While these are severe events, a specific frequency classification (such as Rare or Very Rare) is generally not assigned to these serious events in the documentation.


Q: Why is Calcinin sometimes mentioned in discussions about kidney stones?

Calcinin has a direct mechanistic action on the kidneys where it works to decrease the reabsorption of calcium and phosphate. This results in the increased urinary excretion of these minerals, which is how the body's mineral balance is managed.


Q: What is the general expectation for improvement when using Calcinin?

Clinical trials monitored specific outcomes, including changes in Bone Mineral Density (BMD) and the occurrence of new vertebral fracture events. For Paget’s disease, a common measure of response is monitoring serum alkaline phosphatase levels.


Q: Can Calcinin interact with blood pressure medication?

Official regulatory documents state that formal drug interaction studies, including those with specific blood pressure medications, have not been conducted. Therefore, official data on these potential interactions are not documented.


Q: Is Calcinin used for the prevention of conditions or only for treatment?

Calcinin is described for the treatment of conditions such as Paget’s disease and hypercalcemia. It is also described for the prevention of acute bone loss that may occur due to sudden immobilization in specific patient populations.


Q: Can Calcinin be taken alongside supplements like Vitamin D or magnesium?

The official product information explicitly notes that treatment is recommended with adequate intake of calcium and Vitamin D. Some regulatory documents also note that magnesium compounds may have minor potential interactions, though detailed information is limited.


Q: What kind of monitoring is typically required while on Calcinin treatment?

Monitoring is noted as a requirement during treatment. This may include periodic nasal examinations (if using the nasal spray), periodic re-evaluation for long-term use, and monitoring of serum calcium to check for low calcium levels.


Q: Are there any specific lifestyle changes recommended alongside Calcinin use?

Official labeling specifies that Calcinin treatment is recommended in conjunction with adequate intake of calcium and Vitamin D. This focuses on maintaining appropriate mineral levels in the body.


Q: What is the official recommendation regarding Calcinin use and fertility?

Official documentation states that the effects of the active ingredient on fertility have not been assessed in animals. Furthermore, the nasal spray formulation is officially not indicated for use in females of reproductive potential.

How should Calcinin be stored and disposed of?

How to Store and Dispose of Calcinin? – Official Requirements

Storage & Stability Requirement Official Classification/Statement
Storage Temperature Store at Controlled Room Temperature, which is generally 20 C to 25 C (68 F to 77 F), with excursions permitted between 15 C and 30 C (59 F and 86 F) (USP).
Handling Constraints Do not refrigerate or freeze. Ensure the solution is clear and the seal is intact before administration.
Stability/Use Period This product is a single-dose injection. Any portion unused after a single administration must be discarded.
Disposal Instructions Discard used or expired product and packaging according to all applicable federal, state, and local regulations. The FDA recommends using a drug take-back program or disposing of the item in household trash after mixing it with an undesirable substance, such as kitty litter.
Child Protection All medication, unused portions, and disposal containers must be kept out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Calcinin found in:

A-Z Index: